Release Date: December 10, 2022
Expiration Date: March 2, 2023
Activity Overview
This educational activity is an archive of the live virtual presentation held on December 9, 2022.
For more information about this educational activity, the faculty, and disclosures, please click here.
Target Audience
This activity is directed toward medical oncologists, hematologic oncologists, hematologists, pharmacists, NP/PAs, nurses, and other healthcare professionals involved in the treatment of MPNs.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Determine factors that inform personalized treatment decisions in patients with MF, PV, and ET based on genetics, risk stratification, and symptom burden
- Outline the mechanistic rationale for the application of current and emerging therapeutic approaches for the management of MPNs
- Assess the efficacy and safety profiles of current and emerging therapeutic strategies in MPNs across lines of therapy
- Integrate recent clinical trial evidence and guidelines to individualize decisions among patients with MPNs, including management of treatment-related toxicities
Andrew Kuykendall, MD
Assistant Member, Department of Malignant Hematology
Moffitt Cancer Center
Tampa, FL
Disclosures: Grant/Research Support: Blueprint, Bristol Myers Squibb, MorphoSys, Prelude, Protagonist, Sierra Oncology; Consultant: AbbVie, Biopharma, Blueprint, Bristol Myers Squibb, CTI, GSK, Imago, Incyte, MorphoSys, Novartis, Protagonist; Speakers’ Bureau: Blueprint.
Marina Kremyanskaya MD, PhD
Associate Professor
Tisch Cancer Institute
Icahn School of Medicine at Mount Sinai
New York, NY
Disclosures: Grant/Research Support: Bristol Myers Squibb, Constellation, Incyte, Kronos, Kura, Protagonist; Consultant: AbbVie, CTI, Incyte, MorphoSys/Constellation, Protagonist; Speakers’ Bureau: AbbVie, Celgene
Lucia Masarova, MD
Assistant Professor
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Lucia Masarova, MD, has no relevant financial relationships with ineligible companies.
Douglas A. Tremblay, MD
Assistant Professor of Medicine
Division of Hematology/Oncology
Tisch Cancer Institute
Icahn School of Medicine at Mount Sinai
New York, NY
Disclosures: Grant/Research Support: Astellas, Gilead; Consultant: AbbVie, GSK
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
